Promising drug combo targets Hard-to-Treat amyloidosis
NCT ID NCT05451771
First seen Jun 18, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, venetoclax and dexamethasone, in people with a rare blood disorder called AL amyloidosis that has come back or not improved after treatment. The trial includes 53 adults with a specific genetic marker (t(11;14)). The goal is to find the safest dose and see how well the drugs work at reducing abnormal proteins and improving organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Medical Center
RECRUITINGBoston, Massachusetts, 02118, United States
Contact Phone: •••-•••-••••
Contact
-
Froedtert Hospital & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
New York Presbyterian Hospital/Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Alabama at Birmingham Hospital
WITHDRAWNBirmingham, Alabama, 35294, United States
-
Washington University School of Medicine
ACTIVE_NOT_RECRUITINGSt Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (Venclexta) and dexamethasone
What this could lead to
If successful, this could offer a new treatment option for people with a specific genetic type of AL amyloidosis that has not responded to prior therapy.
What could go wrong
This is an early-phase trial with only 53 participants, so results may not apply broadly. Side effects like low blood counts and tumor lysis syndrome are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.